20 categories

Evidence

Published evidence, read closely. Trial digests, journal club, meta-analyses, preprints, and structured critique.

148 topics7,629 posts42 solved Moderators: s.leclerc, dr_okonkwo About this category

Trials 33 Journal club 47 Meta-analyses 24 Preprints 20 Study critique 24

148 topics · page 2 of 5

Topic	Participants	Replies	Views	Activity
Selection into a registry and what it does to the estimate — a second dataset Evidence › Study critique confounding risk of bias effect size disputed Solved Posting this under the heading it deserves: Selection into a registry and what it does to the estimate — a second dataset Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024).…	+28	32	1.3k	1d
Subgroup analyses: pre-specified versus discovered Evidence › Trials randomised trial intention to treat surrogate endpoints estimand Subgroup analyses: pre-specified versus discovered — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…		2	27k	1d
[2026 update] Journal club: what we got wrong in an earlier session Evidence › Journal club journal club effect size estimand number needed to treat Solved Journal club: what we got wrong in an earlier session — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…	+5	9	4.2k	1d
Publication bias detection and its low power Evidence › Meta-analyses heterogeneity publication bias effect size On the subject in the title: Publication bias detection and its low power Working notes rather than a conclusion. I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not think it…		2	3.2k	1d
Revisiting: How this community labels and discusses unrefereed work Evidence › Preprints needs a source risk of bias preprint effect size Solved Revisiting: How this community labels and discusses unrefereed work Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…	+31	35	7k	1d
Journal club: SUSTAIN 6 and its retinopathy signal Evidence › Journal club estimand effect size risk of bias journal club Under review On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I do not think it…	+110	122	46k	1d
Journal club: orforglipron phase 2 and the non-peptide question Evidence › Journal club journal club estimand randomised trial Journal club: orforglipron phase 2 and the non-peptide question Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in support…	+120	132	13k	1d
A pooled estimate that changed when one trial was added Evidence › Meta-analyses meta-analysis publication bias effect size Solved A pooled estimate that changed when one trial was added — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…	+24	28	3.5k	2d
Coming back to: Why a preprint's supplementary material is often the best part Evidence › Preprints risk of bias effect size preprint Under review Why a preprint's supplementary material is often the best part — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021) with STEP 4 (…	+109	116	36k	2d
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Evidence › Journal club estimand risk of bias number needed to treat Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SUSTAIN 6 ( N Engl…	+108	122	52k	7d
[2026 update] Journal club: FLOW and the renal composite, component by component Evidence › Journal club journal club randomised trial estimand Journal club: FLOW and the renal composite, component by component Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…		2	21k	9d
Interim analyses and stopping rules Evidence › Trials intention to treat surrogate endpoints open label discontinuation & dropout Interim analyses and stopping rules Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in support of a claim I do not think…	+25	29	35k	16d
Revisiting: Journal club: SURMOUNT-1, read without the press release Evidence › Journal club number needed to treat effect size risk of bias journal club Solved On the subject in the title: Revisiting: Journal club: SURMOUNT-1, read without the press release Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…	+54	62	1.5k	26d
Journal club: STEP 3 and the intensive behavioural therapy floor Evidence › Journal club randomised trial journal club effect size risk of bias Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with STEP 4 (…	+6	10	13k	28d
Run-in periods and the population they select Evidence › Trials surrogate endpoints discontinuation & dropout estimand randomised trial On the subject in the title: Run-in periods and the population they select Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…	+130	142	7.3k	1mo
Journal club: SELECT, absolute risk, and how it was reported Evidence › Journal club journal club estimand randomised trial effect size Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024). Please read…		2	52k	1mo
Second pass at: A pooled estimate that changed when one trial was added Evidence › Meta-analyses effect size risk of bias publication bias meta-analysis Wiki On the subject in the title: Second pass at: A pooled estimate that changed when one trial was added Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it before…	+26	30	22k	1mo
Journal club: SELECT, absolute risk, and how it was reported — a second dataset Evidence › Journal club risk of bias effect size randomised trial journal club On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SELECT ( N…		4	1.3k	1mo
Reading a trial's population section before its results Evidence › Trials estimand surrogate endpoints discontinuation & dropout randomised trial Solved On the subject in the title: Reading a trial's population section before its results Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do not think it…	+91	109	22k	2mo
Adjudicated events and why the definition matters Evidence › Trials estimand intention to treat discontinuation & dropout surrogate endpoints Under review On the subject in the title: Adjudicated events and why the definition matters Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before posting; the…		2	4.5k	2mo
How this community labels and discusses unrefereed work — the long version Evidence › Preprints needs a source effect size risk of bias Asking directly, because I could not find a straight answer: How this community labels and discusses unrefereed work — the long version I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a…	+18	23	21k	2mo
Revisiting: Primary endpoint hierarchies and why order matters Evidence › Trials estimand surrogate endpoints discontinuation & dropout intention to treat Posting this under the heading it deserves: Revisiting: Primary endpoint hierarchies and why order matters Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with SURPASS-2 ( N…	+21	25	46k	3mo
Subgroup analyses: pre-specified versus discovered — a second dataset Evidence › Trials open label discontinuation & dropout estimand randomised trial On the subject in the title: Subgroup analyses: pre-specified versus discovered — a second dataset Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-4 ( Lancet ,…	+71	79	906	3mo
Publication bias detection and its low power — does this still hold? Evidence › Meta-analyses publication bias risk of bias meta-analysis heterogeneity Solved The question in the title: Publication bias detection and its low power — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen LEADER ( N Engl J Med , 2016)…	+24	28	2.4k	3mo
The "under review" status pill and when a moderator applies it Evidence › Preprints risk of bias effect size preprint Posting this under the heading it deserves: The "under review" status pill and when a moderator applies it Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it…	+96	119	17k	3mo
Primary endpoint hierarchies and why order matters Evidence › Trials randomised trial intention to treat estimand Primary endpoint hierarchies and why order matters Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with SURPASS-2 ( N Engl J…		4	308	3mo
Journal club: is percentage weight change the right endpoint? Evidence › Journal club number needed to treat randomised trial journal club Solved Journal club: is percentage weight change the right endpoint? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SURPASS-4 ( Lancet , 2021) with SURMOUNT-OSA (…	+116	120	23k	3mo
Coming back to: Measurement error in a self-reported exposure Evidence › Study critique risk of bias observational data effect size disputed Measurement error in a self-reported exposure — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…	+23	27	49k	3mo
[2026 update] Composite endpoints and the component doing the work Evidence › Trials surrogate endpoints discontinuation & dropout estimand On the subject in the title: Composite endpoints and the component doing the work Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-4 ( Lancet , 2021) and…	+76	87	994	3mo
Follow-up: What a statistical analysis plan adds that the paper does not Evidence › Trials randomised trial estimand open label surrogate endpoints What a statistical analysis plan adds that the paper does not I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…		2	7.2k	3mo